Osphena vs Duavee: Long-Term Durability of Response for Menopause Symptoms

What Are Osphena and Duavee, and How Do They Work?

Both Osphena and Duavee are non-progestogen oral options for postmenopausal women who cannot or prefer not to use conventional estrogen-plus-progestogen hormone therapy. They work by entirely different mechanisms, which is why they treat different symptom clusters and carry different risk profiles.

Ospemifene (Osphena): selective estrogen receptor modulator

Ospemifene is a selective estrogen receptor modulator (SERM). Like tamoxifen and raloxifene, it acts as an estrogen agonist in some tissues and an antagonist in others. In the vaginal epithelium and lower urinary tract, it behaves as a partial estrogen agonist, rebuilding the mucosal lining that thins after estrogen drops at menopause. FDA approval labeling confirms ospemifene 60 mg daily is indicated for moderate-to-severe dyspareunia and moderate-to-severe vaginal dryness, both symptoms of vulvovaginal atrophy (VVA), also called genitourinary syndrome of menopause (GSM).

Because ospemifene has no systemic estrogenic effect on the uterine endometrium in the agonist direction at clinical doses, it does not require a progestogen to protect the uterus. This is a key practical advantage for women who cannot tolerate progestogens.

Conjugated estrogens/bazedoxifene (Duavee): tissue-selective estrogen complex

Duavee pairs conventional conjugated equine estrogens (CEE 0.45 mg) with bazedoxifene (BZA 20 mg), a SERM that acts as an estrogen antagonist in the uterus and breast. The CEE delivers systemic estrogen for hot flash relief and bone protection. The BZA replaces the progestogen, blocking estrogen's stimulatory effect on endometrial tissue. The SMART (Selective estrogens, Menopause, And Response to Therapy) trial series demonstrated that CEE 0.45 mg/BZA 20 mg significantly reduced hot flash frequency and severity versus placebo at 12 weeks and maintained this effect through 24 months.

This combination is designed specifically for postmenopausal women who have an intact uterus and who need systemic symptom control without adding a progestogen.

Durability of Response: What the Trial Data Actually Show

This is the question that matters most for long-term treatment decisions: does the benefit hold? Here is what the evidence shows for each drug, head to head with the data.

Osphena durability: 52-week data

The key ospemifene VVA RCT, a phase 3 double-blind placebo-controlled study, enrolled 826 postmenopausal women with moderate-to-severe dyspareunia and followed them for 12 weeks. At week 12, ospemifene 60 mg produced statistically significant improvements in the percentage of parabasal cells, superficial cells, vaginal pH, and the most bothersome symptom score compared with placebo. A 40-week open-label safety extension then followed participants out to 52 weeks total, confirming that vaginal maturation index improvements were maintained and that no new safety signals emerged.

Key durability findings from the ospemifene clinical program:

• Vaginal pH normalized from a postmenopausal average above 5.0 to below 5.0 in most treated women by week 12, and remained in that range at week 52.
• The percentage of superficial cells (the marker of estrogenic maturation) continued to rise through the extension period, suggesting a progressive, not plateau, tissue response.
• Dyspareunia severity scores showed sustained improvement without dose escalation.

There are no published randomized controlled trials of ospemifene beyond 52 weeks. Real-world registry data and post-marketing surveillance suggest continued tolerability, but head-to-head durability data beyond one year do not exist for this drug. This evidence gap should be acknowledged plainly: long-term durability past 52 weeks is extrapolated from open-label data and mechanism, not from controlled trials.

Duavee durability: 24-month data from SMART trials

The SMART trial series is the most complete long-term dataset for CEE/BZA. SMART-5, a 24-month randomized trial, showed that CEE 0.45 mg/BZA 20 mg significantly reduced weekly vasomotor symptom (VMS) frequency by approximately 74% from baseline at month 3, and this reduction was maintained through month 24 without attenuation. Bone mineral density (BMD) at the lumbar spine improved by 1.5% versus a loss of 1.2% in the placebo group over 24 months, a clinically meaningful separation.

Endometrial safety was confirmed across the SMART series: cumulative endometrial hyperplasia rates with CEE/BZA were below 1%, equivalent to placebo, and no cases of endometrial carcinoma were attributed to the study drug. This is the central safety proof-of-concept for the TSEC category.

Breast density, which increases with conventional CEE plus medroxyprogesterone acetate (MPA) and complicates mammogram interpretation, did not increase with CEE/BZA in the SMART program. This is a practical advantage for women undergoing annual breast imaging.

Head-to-head comparison: no direct trial exists

No randomized controlled trial has compared ospemifene directly to CEE/BZA. Any "comparison" in this article and elsewhere is inferential, drawing on separate placebo-controlled trial arms, different enrolled populations, and different primary endpoints. A woman reading this should weight that limitation. The two drugs treat different primary symptoms, so a true head-to-head would require a composite endpoint that clinical trialists have not attempted.

Symptom Coverage: Matching the Drug to Your Menopause Profile

Choosing between these two drugs depends almost entirely on which symptoms are driving your quality-of-life concerns.

If vaginal dryness and painful sex are your main problem

Ospemifene is the right starting point. It is the only oral SERM with an FDA indication specifically for dyspareunia and vaginal dryness from GSM. Women who cannot use or prefer to avoid vaginal estrogen creams, rings, or tablets often find an oral option appealing. ACOG Practice Bulletin on GSM notes that systemic and local therapies are both appropriate for moderate-to-severe GSM, and that oral options may suit women with dexterity issues or preference.

Duavee can improve vaginal symptoms secondarily through its systemic estrogen component, but its FDA label does not carry a GSM indication. The vaginal benefit from CEE/BZA is a secondary outcome in the SMART trials, not the primary treatment target.

If hot flashes are disabling your sleep and daily function

Duavee is the more direct therapy. It delivers systemic estrogen, which ospemifene does not. Ospemifene has no clinical trial evidence for reducing hot flash frequency or severity, and its SERM mechanism means it may cause or worsen hot flashes in some women, the same way tamoxifen does.

The Menopause Society (formerly NAMS) 2023 hormone therapy position statement affirms that systemic estrogen-based therapy remains the most effective treatment for VMS, with CEE/BZA listed as an appropriate option for women with an intact uterus.

If bone protection matters in your decision

Duavee carries an FDA indication for prevention of postmenopausal osteoporosis. Ospemifene does not carry a bone indication, though SERMs as a class (raloxifene being the clearest example) can have bone-protective effects. Post-hoc and mechanistic analyses suggest ospemifene may have some positive effect on bone turnover markers, but no fracture reduction data exist for ospemifene, and prescribing it for bone protection off-label is not supported by the current evidence.

Sex-Specific Physiology: How Hormonal Status Changes Everything

Both drugs are postmenopause-only treatments, but the hormonal context within postmenopause still matters. A woman who is two years past her last period and has severe hot flashes plus GSM is in a different physiological state than a woman who is fifteen years postmenopause with atrophic vaginitis as her sole complaint.

Perimenopause

Neither drug is approved for or well-studied in perimenopausal women. Ospemifene requires confirmed postmenopausal status (or at minimum, estrogen-deficient state) to exert its tissue-selective effects in vaginal mucosa. Duavee has not been studied in women with irregular cycles or fluctuating ovarian function. Use in perimenopause is off-label for both.

Early postmenopause (within 10 years of final menstrual period)

This is the primary target population for both drugs and where most trial data were collected. Women in this group tend to have more pronounced VMS, more rapid bone loss, and early GSM changes. The timing hypothesis for estrogen therapy, supported by observational data, suggests cardiovascular benefits are more likely when therapy is initiated in this window. CEE/BZA has not been specifically tested for cardiovascular outcomes, but the systemic estrogen component raises the same timing considerations as conventional HRT.

Late postmenopause (more than 10 years from final menstrual period)

Ospemifene's local-tissue mechanism makes it broadly applicable across the postmenopausal lifespan for GSM. Long-term GSM is common: up to 84% of postmenopausal women report at least one GSM symptom, and symptom severity often increases with time since menopause without treatment. For late postmenopausal women whose only bothersome symptom is GSM, ospemifene may be the more targeted choice. Initiating systemic estrogen therapy (via Duavee) more than 10 years post-menopause carries theoretical cardiovascular concerns from the timing hypothesis, though the absolute risk from CEE/BZA at the low 0.45 mg CEE dose has not been established in this subgroup.

Pregnancy, Lactation, and Contraception

Both drugs are contraindicated in pregnancy. This section is required because postmenopausal status is assumed but not always confirmed before prescribing.

Ospemifene in pregnancy and lactation

Ospemifene is FDA Pregnancy Category X (under the older system) and is classified as contraindicated in pregnancy under current labeling. Animal reproduction studies show fetal harm, and there are no adequate human data in pregnant women. If a woman of reproductive age is prescribed ospemifene off-label for any reason, reliable contraception is mandatory. Ospemifene is not studied in lactating women. Because it distributes into tissues with estrogenic activity and its effects on a nursing infant are unknown, breastfeeding is not recommended during use.

Conjugated estrogens/bazedoxifene in pregnancy and lactation

CEE/BZA is contraindicated in pregnancy. Estrogens can cause fetal harm, and bazedoxifene as a SERM carries the same teratogenicity concerns as other members of this drug class. No human pregnancy data exist for this specific combination. The drug is not indicated in premenopausal women, but if prescribed off-label to a perimenopausal woman who has not confirmed anovulation, contraception is required. Estrogens are known to pass into breast milk and can suppress lactation. CEE/BZA should not be used during breastfeeding.

Clinical bottom line: both drugs are postmenopause-only. Confirm menopause (12 consecutive months of amenorrhea, or FSH above 40 mIU/mL in a clinical context) before initiating either therapy.

Safety Profiles Side by Side

Venous thromboembolism risk

Ospemifene carries a boxed warning for VTE, derived from its SERM class mechanism rather than large observed event rates in trials. The absolute risk increase in the clinical program was small, but women with personal or family history of DVT or pulmonary embolism should discuss this risk explicitly before starting.

Duavee also carries a VTE warning from its estrogen component. Oral estrogens, including CEE, are associated with higher VTE risk than transdermal estrogen formulations, though the absolute rate with CEE 0.45 mg is lower than with higher CEE doses studied in the WHI (0.625 mg CEE). The WHI demonstrated a hazard ratio of approximately 2.06 for VTE with oral CEE plus MPA versus placebo, though CEE/BZA uses a lower CEE dose and no MPA, so direct extrapolation is imprecise.

Breast safety

Ospemifene acts as an estrogen antagonist in breast tissue (the same direction as tamoxifen), which is why its breast safety profile is generally considered favorable and it may even carry a theoretical breast cancer risk-reduction effect, though this has not been confirmed in fracture or cancer-outcome trials.

CEE/BZA does not increase mammographic breast density, unlike CEE plus MPA. Breast density data from the SMART trials showed no significant change from baseline with CEE 0.45 mg/BZA 20 mg at 24 months, compared with increases seen with CEE/MPA in historical trial data.

Hot flash side effect with ospemifene

Because ospemifene is a SERM, some women experience hot flashes as a side effect, particularly in the first few weeks of use. This occurs in approximately 7-8% of women in clinical trials and is the most commonly reported adverse event leading to discontinuation. Women who already have moderate-to-severe VMS should be counseled that ospemifene might transiently worsen their hot flashes.

Who This Is Right For, and Who Should Consider the Other Option

The following decision framework is developed by the WomanRx clinical editorial team to organize the evidence by patient profile. No published guideline yet provides this specific head-to-head framing.

Choose ospemifene (Osphena) if you:

• Have moderate-to-severe vaginal dryness or dyspareunia as your primary complaint
• Prefer or require an oral (non-vaginal) treatment for GSM
• Cannot or prefer not to use a progestogen
• Have a history of breast cancer risk concerns that favor SERM-class therapy (discuss with your oncologist; ospemifene is not approved for breast cancer survivors and the evidence is limited)
• Tolerate or have already managed hot flashes separately

Choose CEE/BZA (Duavee) if you:

• Have an intact uterus and moderate-to-severe hot flashes as your primary or co-primary complaint
• Want bone protection built into your menopause therapy
• Cannot tolerate progestogens (Duavee eliminates the need for them)
• Are comfortable with systemic estrogen exposure
• Are within 10 years of your final menstrual period (most trial data concentrated here)

Neither drug is appropriate if you:

• Are pregnant or trying to conceive
• Have a history of estrogen-receptor-positive breast cancer (discuss ospemifene's SERM status with your oncologist; Duavee contains systemic estrogen and is generally avoided)
• Have active VTE, liver disease, or unexplained vaginal bleeding
• Have had a hysterectomy and want systemic estrogen (for you, estrogen alone without bazedoxifene is simpler and well-studied)

Switching from Osphena to Duavee: What to Expect

Switching between these drugs is clinically reasonable if your symptom profile changes or one drug fails to meet your needs. Here is what the switch typically looks like in practice.

Why women switch

The most common clinical scenario is a woman who starts ospemifene for GSM and then develops worsening hot flashes that ospemifene cannot address (and may worsen). At that point, switching to or adding a systemic therapy makes sense.

Conversely, a woman on Duavee may find that her hot flashes resolve but her vaginal symptoms persist despite systemic estrogen. For her, switching to or adding ospemifene specifically for GSM, or adding vaginal estrogen, may provide additional mucosal benefit, though combining a SERM with systemic estrogen is off-label and not supported by RCT data.

Washout and transition

There is no established washout period when switching between these drugs based on published guidelines. Ospemifene has a half-life of approximately 26 hours, reaching steady state within 7 days. CEE/BZA reaches steady-state pharmacokinetics within a similar timeframe. A practical approach used in clinical practice is to stop one drug and start the other on consecutive days, though your prescribing clinician should confirm based on your full medical history.

What you may feel during the switch

Women switching from ospemifene to Duavee often notice:

• Hot flash reduction within 2 to 4 weeks as systemic estrogen takes effect
• Continued or improved vaginal symptom control from the estrogen component of Duavee
• Possible mild breast tenderness as systemic estrogen is introduced

Women switching from Duavee to ospemifene may notice:

• Return or worsening of hot flashes within 2 to 4 weeks as systemic estrogen is removed
• Continued vaginal mucosal support from ospemifene's local estrogenic effect
• A 7-8% chance of new-onset hot flashes as a direct SERM side effect

Female-Relevant Conditions: PCOS, Endometriosis, and Other Comorbidities

PCOS in the postmenopausal transition

Women with a history of PCOS often enter perimenopause and menopause with insulin resistance, elevated cardiovascular risk, and a history of anovulation that may complicate confirming menopause. Neither drug has been studied in this specific subgroup. For postmenopausal women with PCOS history who have GSM and hot flashes, the choice between these drugs follows the same symptom-based logic, but metabolic monitoring is appropriate given their baseline risk profile.

Endometriosis history

Women with endometriosis history who are postmenopausal require careful prescribing because residual endometrial deposits can theoretically respond to systemic estrogen. Ospemifene, as a SERM with no systemic estrogenic activity at the endometrium, may be a safer choice for GSM in this group. Duavee contains systemic CEE, which could theoretically stimulate residual endometriosis implants, though evidence in this specific context is lacking. ACOG advises caution when prescribing systemic estrogen after surgical menopause in women with endometriosis.

Female pattern hair loss and metabolic health

Neither drug has established evidence for improving female pattern hair loss. Some SERM-class drugs have studied androgenic effects on hair, but ospemifene's receptor selectivity profile does not suggest meaningful effect in this area. For metabolic health, the systemic estrogen in Duavee may modestly improve lipid profiles (CEE raises HDL and lowers LDL in most women), though clinical prescribing solely for lipid management is not supported.

Monitoring and How Long to Stay on Each Drug

Both drugs are approved for ongoing use without a specified time limit, though the FDA label for each recommends using the lowest effective dose for the shortest duration consistent with treatment goals. This is the standard language for hormone-related therapies and reflects precaution rather than a demonstrated harm signal at specific durations.

For ospemifene, the 52-week RCT data support at least one year of continuous use. Beyond that, clinical judgment and annual symptom reassessment guide continuation.

For Duavee, the 24-month SMART-5 data support two years with maintained efficacy and endometrial safety. Annual gynecological review, including endometrial assessment if any breakthrough bleeding occurs, is standard. Mammography should continue per usual age-based screening intervals.

The Menopause Society recommends that women not arbitrarily discontinue effective hormone therapy at age 65, and that decisions be individualized based on symptom burden, risk profile, and patient preference.